NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $18.69 -0.13 (-0.69%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$18.11▼$18.9150-Day Range$18.08▼$25.3852-Week Range$17.52▼$45.00Volume292,061 shsAverage Volume496,774 shsMarket Capitalization$503.36 millionP/E RatioN/ADividend YieldN/APrice Target$71.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Arcturus Therapeutics alerts: Email Address Arcturus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside282.0% Upside$71.40 Price TargetShort InterestBearish22.11% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.45Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.60) to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector627th out of 910 stocksPharmaceutical Preparations Industry286th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.11% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Arcturus Therapeutics has recently increased by 1.87%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth.Dividend SustainabilityBased on EPS estimates, Arcturus Therapeutics will have a dividend payout ratio of 357.50% in the coming year. This indicates that Arcturus Therapeutics may not be able to sustain their current dividend.Read more about Arcturus Therapeutics' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 1.4 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.60) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Arcturus Therapeutics Stock (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Stock News HeadlinesSeptember 4 at 2:57 PM | markets.businessinsider.comBuy Rating Affirmed: Arcturus Therapeutics’ Promising Cystic Fibrosis Program ProgressSeptember 4 at 4:31 AM | americanbankingnews.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200-Day Moving Average of $28.74September 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 28, 2024 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Consensus Price Target from BrokeragesAugust 28, 2024 | americanbankingnews.comBrokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $71.40August 22, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on Soleno Therapeutics (SLNO)August 17, 2024 | finance.yahoo.comARCT Mar 2025 25.000 call (ARCT250321C00025000)August 13, 2024 | msn.comLeerink Partners Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Outperform RecommendationSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... August 9, 2024 | seekingalpha.comHigh-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive VaccineAugust 7, 2024 | markets.businessinsider.comArcturus Therapeutics: Buy Rating Affirmed Amid Kostaive Launch and ARCT-810 Clinical AdvancementsAugust 7, 2024 | finance.yahoo.comArcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline ProgressAugust 6, 2024 | insidermonkey.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2024 Earnings Call TranscriptAugust 5, 2024 | ca.finance.yahoo.comARCT Aug 2024 17.500 callAugust 4, 2024 | markets.businessinsider.comHere's what to expect from Arcturus Therapeutics's earningsAugust 1, 2024 | finance.yahoo.comArcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth ConferenceJuly 23, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)July 18, 2024 | businesswire.comArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024See More Headlines Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$71.40 High Stock Price Target$90.00 Low Stock Price Target$48.00 Potential Upside/Downside+282.0%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-41.21% Pretax Margin-42.27% Return on Equity-25.47% Return on Assets-16.25% Debt Debt-to-Equity RatioN/A Current Ratio3.78 Quick Ratio3.78 Sales & Book Value Annual Sales$147.03 million Price / Sales3.42 Cash FlowN/A Price / Cash FlowN/A Book Value$9.60 per share Price / Book1.95Miscellaneous Outstanding Shares26,932,000Free Float23,215,000Market Cap$503.36 million OptionableOptionable Beta2.64 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 52)Founder, President, CEO & Director Comp: $1.13MDr. Padmanabh Chivukula Ph.D. (Age 45)Founder, Chief Scientific Officer, COO & Secretary Comp: $787.5kMr. Andrew H. Sassine MBA (Age 60)CFO & Director Comp: $826.88kMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Lance KurataChief Legal OfficerMs. Natash O. BowmanChief Human Resources OfficerMr. Kevin T. SkolChief Business OfficerDr. Juergen Froehlich FCPh (Age 68)M.D., MBA, Chief Medical Officer Dr. Igor Smolenov M.D.Ph.D., Chief Development OfficerJoseph RobertsControllerMore ExecutivesKey CompetitorsRevance TherapeuticsNASDAQ:RVNCStoke TherapeuticsNASDAQ:STOKMersana TherapeuticsNASDAQ:MRSNShattuck LabsNASDAQ:STTKNGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 91,224 shares on 8/19/2024Ownership: 0.907%Deerfield Management Company L.P. Series CBought 39,328 shares on 8/15/2024Ownership: 0.146%Scientech Research LLCBought 15,377 shares on 8/15/2024Ownership: 0.057%AQR Capital Management LLCSold 62,525 shares on 8/15/2024Ownership: 0.043%Point72 Asia Singapore Pte. Ltd.Bought 5,852 shares on 8/15/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $31.53 on January 1st, 2024. Since then, ARCT stock has decreased by 40.7% and is now trading at $18.69. View the best growth stocks for 2024 here. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its earnings results on Monday, August, 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($1.85) by $1.21. The biotechnology company had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 25.47% and a negative net margin of 41.21%. When did Arcturus Therapeutics' stock split? Arcturus Therapeutics's stock split before market open on Saturday, January 1st 2000. The 7-1 split was announced on Saturday, January 1st 2000. The newly created shares were issued to shareholders after the closing bell on Thursday, November 16th 2017. An investor that had 100 shares of stock prior to the split would have 700 shares after the split. What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' top institutional investors include Federated Hermes Inc. (17.43%), ARK Investment Management LLC (7.30%), Sumitomo Mitsui Trust Holdings Inc. (5.80%) and Dimensional Fund Advisors LP (3.41%). Insiders that own company stock include Pad Chivukula, Magda Marquet and Keith C Kummerfeld. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK) and NVIDIA (NVDA). This page (NASDAQ:ARCT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts